Respiratory Syncytial Virus (RSV) is one of the most common causes of childhood lower respiratory tract infection (LRTI) worldwide. Accurate data are critical to inform the rationale for RSV vaccine and immunoprophylaxis development. We evaluated the burden of laboratory-confirmed RSV from ...
No vaccines for RSV are in use. Because of immunosenescence, the immunologic requirements for a successful RSV vaccine in the elderly might differ from a RSV vaccine for young children. Using an aged mouse model of RSV pathogenesis, we found that aged mice had impaired Agspecific CD8+ T cell...
Based on the strength and flexibility of Adimab's platform, ... - Asia-Pacific Biotech News 被引量: 0发表: 2013年 Industry Watch Veeda Oncology Announces $8.4 million in New Business. Medicago signs Vaccine MOU with PT Bio Farma. Kyowa Hakko Kirin to Enter Out-licensing Agreement ... - ...
Methods: We focused on developing a broad-spectrum vaccine that activates the immune system to directly combat RSV. The objective of this study is to identify CD4 and CD8 T-cell epitopes using an immunoinformatics approach to develop RSV vaccines. The efficacy of these...
Human respiratory syncytial virus (RSV) is the leading viral cause of acute pediatric lower respiratory tract infections worldwide, with no available vaccine or effective antiviral drug. To gain insight into virus-host interactions, we performed a genome-wide siRNA screen...
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants worldwide. Despite decades of research, there is still no registered vaccine available for this major pathogen. We investigated the protective efficacy of a recombinant influenza virus, PR8/NA-F...
This communication describes the total in vivo blockade of the tumour produced by Rous sarcoma virus (RSV), an avian subgroup. A leuco-virus2,3, by a vaccine strain of rabies virus (RV), a rhabdovirus2.SURSHM. DSANatureNature
Therefore, we underscore the importance of developing prevention strategies for these viruses in Ethiopia and support the importance of developing and introducing an effective vaccine against these viruses.doi:10.1186/s12985-023-02131-xWadilo, Fiseha...
A successful vaccine against human RSV (HRSV) is likely to induce a Th1 or a balanced Th1/TH2 cytokine response. We tested a panel of HRSV immunostimulating complexes (ISCOMs) containing different Quillaja saponin fractions (QH-A, QH-C, and 703: a mixture of 70% QH-A and 30% QH-C)...
Respiratory syncytial virus (RSV) is a major cause of morbidity from respiratory infection in infants, young children and the elderly. No effective vaccine against RSV is currently available and studies of the natural history of RSV infection suggest repeated infections with antigenically related virus...